IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 67.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,637 shares of the medical research company’s stock after acquiring an additional 3,894 shares during the quarter. Simplify Asset Management Inc.’s holdings in IQVIA were worth $2,284,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. 1832 Asset Management L.P. grew its position in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of IQVIA during the second quarter worth about $70,610,000. Impax Asset Management Group plc raised its stake in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after purchasing an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in IQVIA by 285.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after acquiring an additional 198,808 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Stock Down 5.7 %

IQVIA stock traded down $11.61 during midday trading on Friday, hitting $191.33. 1,199,209 shares of the company were exchanged, compared to its average volume of 1,128,225. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $191.28 and a fifty-two week high of $261.73. The company’s fifty day moving average price is $227.96 and its 200-day moving average price is $228.59. The company has a market cap of $34.73 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.17 and a beta of 1.51.

Analyst Ratings Changes

IQV has been the topic of a number of research reports. Evercore ISI lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.